Opinion|Videos|October 7, 2024
Exploring PD-1/PD-L1 Pathways and Innovative Treatments for NMIBC
Key Takeaways
- PD-1/PD-L1 pathways are pivotal in cancer immunotherapy, enabling tumor immune evasion by inactivating T-cells through receptor-ligand interactions.
- Investigational agents in BCG-naive and unresponsive settings include gene therapy and intravesical treatments, targeting enhanced immune activation.
Panelists discuss how the PD-1/PD-L1 pathway plays a crucial role in cancer immunotherapy, outlining its mechanisms of action and highlighting the agents currently being investigated for patients who are BCG-naive or unresponsive, including gene therapy and intravesical options.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What is the role of the PD-1/PD-L1 pathways in cancer immunotherapy?
- What are their mechanisms of action?
What agents are being investigated in the BCG-naive and unresponsive setting? Gene therapy, intravesical?
Advertisement
Related to this article
Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
In RTOG 3506, adding enzalutamide to standard ADT and salvage radiotherapy was associated with 2-year PFS benefit.
Armine K. Smith, MD, discusses the importance of integrating sexual health into bladder cancer care, including proactive counseling, preservation strategies, and multidisciplinary support.
In the phase 3 PACE-A trial, SBRT and prostatectomy showed similar 8-year disease control in localized prostate cancer, with lower rates of urinary incontinence after SBRT.
Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
The registrational study is designed to evaluate the diagnostic performance of 68Ga-DOTA-RM2 vs histopathology in prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants fast track designation to pre-biopsy 68Ga-PSMA-PET program
2
Enzalutamide plus salvage radiotherapy associated with improved PFS in high-risk BCR
3
Brian Mazzarella, MD, reviews early data on water vapor therapy for localized prostate cancer
4
Pivotal trial launches of GRPR-targeted PET imaging agent in prostate cancer
5